Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen. However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine. To help put this debate into context, here is a new educational video that helps explain how prescription drug costs are really determined and where the pharmaceutical dollar actually goes.Continue reading
A unified coalition of health care professionals and community advocates from throughout Arizona are speaking up to strongly oppose two sets of vaccine related bills currently under consideration in the Arizona Legislature. (HB 2470, 2471, 2472 and SB1114, 1115, 1116).
Vaccination is one of the cornerstones of preventing disease and improving the health of our society.
They are speaking out and you can too.Continue reading
H.R. 184 the Protect Medical Innovation Act which would repeal the Medical Device Excise Tax passed in the U.S House of Representatives on July 24, 2018. (283 Ayes; 132 Nayes; 13 Not Voting) Seven members of Arizona’s nine person House Delegation both co-sponsored and voted in support of of the bill. The next step is the Senate. Continue reading
The countdown clock is ticking on the status of federal funding and the end of the two-year suspension of the medical device tax. First payments on the medical device tax are due to be made in just 12 days.Continue reading
On April 14, 2017, the leaders of the Senate and House health committees released a discussion draft of bipartisan legislation reauthorizing the Food and Drug Administration user fee agreements. Continue reading
AZBio delivered data on life-changing innovation and the economic impact of Arizona’s life sciences industry to Arizona’s Congressional Delegation last week in meetings with 10 of Arizona’s 11 Congressional offices.